Besides, we delineated the genomic features of WDHD1 at the pan-cancer level, including expression and mutations, and explored for the first time the relationship between its paclitaxel and rapamycin resistance, tumor heterogeneity, RNA methylation modification, MYC, and E2F pathways. The gene discussed is MYC; the disease is neoplasm.